Bessemer Group’s NovoCure NVCR Stock Holding History

Bessemer Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-81	Closed	-$1K	–	2656
2025 Q3	$1K	Buy	81 +10	+14%	+$134	﹤0.01%	2432
2025 Q2	$1K	Hold	71	–	–	﹤0.01%	2325
2025 Q1	$1K	Buy	+71	New	+$1.61K	﹤0.01%	2362
2024 Q2	–	Sell	-17,390	Closed	-$272K	–	2107
2024 Q1	$272K	Hold	17,390	–	–	﹤0.01%	945
2023 Q4	$260K	Hold	17,390	–	–	﹤0.01%	979
2023 Q3	$281K	Hold	17,390	–	–	﹤0.01%	954
2023 Q2	$722K	Hold	17,390	–	–	﹤0.01%	704
2023 Q1	$1.05M	Hold	17,390	–	–	﹤0.01%	577
2022 Q4	$1.28M	Hold	17,390	–	–	﹤0.01%	532
2022 Q3	$1.32M	Hold	17,390	–	–	﹤0.01%	532
2022 Q2	$1.21M	Hold	17,390	–	–	﹤0.01%	535
2022 Q1	$1.44M	Hold	17,390	–	–	﹤0.01%	416
2021 Q4	$1.31M	Buy	+17,390	New	+$1.75M	﹤0.01%	417

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Bessemer Group's NVCR Position: Q4 2025 in Review

Bessemer Group sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 81 shares — an estimated $1K sold.

Bessemer Group first reported a position in NVCR in Q4 2021 and held it in 13 quarters. The position peaked at $1.44M in Q1 2022. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

Bessemer Group reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
Bessemer Group sold 81 NovoCure shares in Q4 2025, an estimated $1K.
Bessemer Group first reported a position in NovoCure in Q4 2021 and held it in 13 quarters.
Bessemer Group's NovoCure position peaked at $1.44M in Q1 2022.
238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Bessemer Group's 13F filing for Q4 2025, filed 5 Feb 2026.